Children’s Oncology Group and Signify Health Collaborate to Broaden In-Home Administration for AALL1731 Study

The Children’s Oncology Group (COG) and Signify Health, Inc. have announced a partnership to facilitate clinical trial participation for pediatric patients through in-home clinical services.

Through this new collaboration, pediatric patients participating in COG Study AALL1731, a clinical trial for a therapy to treat B-cell acute lymphoblastic leukemia (B-ALL), now have expanded options to facilitate receipt of experimental treatment at home. AALL1731 (NCT03914625) is sponsored by the National Cancer Institute under a Cooperative Research and Development Agreement (CRADA) with Amgen and is currently open at 195 U.S. COG sites. This in-home infusion service is for the patients assigned to receive blinatumomab on AALL1731 who are unable to access outpatient pumps and homecare. Amgen has provided funding to NCI under the CRADA to support more pediatric patients to receive blinatumomab at home.

For more information, click here.